Monitor early prescription data and physician adoption of the OBI formulation over the next 2-4 quarters. Key competitive risk is Johnson & Johnson's Darzalex (daratumumab), which also has SC formulations. Any market share shifts will be visible in Sanofi's quarterly oncology segment reporting.
Drug in focus
SNY drug pipeline →Sarclisa
● Neutral Named in this 6-K- Impact
- Phase
- Approved / marketed (IV since 2020, SC since 2026); additional Phase 2/3 studies completed or ongoing.
- Time to market
- Already approved and marketed: IV formulation since March 2020; subcutaneous 'Sarclisa Escena' formulation approved July 9, 2026.
- Next catalyst
- None dated
What to watchWatch Sanofi's quarterly earnings disclosures for Sarclisa/Sarclisa Escena sales growth and launch uptake of the new subcutaneous on-body-injector form, plus any data presentations from completed isatuximab trials (a Phase 3 IV-vs-SC study finished primary completion Jan 30, 2026).
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $44.66entry
- T+1 · 4mo ago −1.52%α −1.36% · $43.98
- T+5 · 4mo ago −2.91%α −2.22% · $43.36
- T+20 · 3mo ago −2.10%α −6.55% · $43.72
- T+60 · 5w ago −11.02%α −15.70% · $39.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indications, making it the first anticancer treatment administered via an on-body injector. The approval, supported by the Phase 3 IRAKLIA study showing non-inferior efficacy with shorter administration time and fewer infusion reactions, strengthens Sarclisa's competitive positioning and may drive adoption through improved patient convenience.
Key Facts
- FDA approved subcutaneous Sarclisa Escena across all existing IV indications for multiple myeloma
- First anticancer treatment to be administered via an on-body injector (CirCLIQ OBI)
- IRAKLIA Phase 3 study demonstrated non-inferior ORR (71.1% SC vs 70.5% IV) with significantly fewer systemic administration reactions (1.5% vs 25%)
- Sarclisa has been prescribed to over 70,000 patients worldwide and is approved in nearly 60 countries
Financial Impact
Positive but unquantified; the SC formulation may expand Sarclisa's addressable patient population and improve treatment convenience, potentially increasing market share against competitors like Darzalex. No specific revenue guidance provided.
Risk Factors
- Competition from Darzalex SC (J&J) which already has a subcutaneous formulation
- Adoption may be slower if providers are reluctant to adopt new administration devices
- No incremental efficacy benefit over IV formulation; differentiation is purely convenience-based
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-306689 |
| Document: d106024d6k.htm | 0001193125-26-306689 |
| Document: 0001193125-26-306689-index-headers.html | 0001193125-26-306689 |
| Document: 0001193125-26-306689-index.html | 0001193125-26-306689 |
| Document: 0001193125-26-306689.txt | 0001193125-26-306689 |
Track record
15 reports on SNY
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
- Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
- Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
- Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
- Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
- Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
- Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
- Jul 31, 202615w ago Court Ruling Bullish 5/10 Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers